On Tuesday, January 11, the Centers for Medicare and Medicaid Services (CMS) announced that it proposes to cover U.S. FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease under Coverage with Evidence Development in CMS-approved randomized controlled trials. Here is the SNMMI’s reaction.
Category: Billing & Reimbursement
The House joined the Senate in passing the bill to suspend the medical device tax. It passed 81-18 in the Senate and 266-150 in the House.Read More
Called ZiPP, the tool is designed to provide radiology practices with strategic information about their business in order to gain a competitive edge.Read More